Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 8, 2020Latest Initiative of #ThisIsMBC "Perseverance" to be Unveiled at the 2020 Virtual San Antonio Breast Cancer Symposium
Eisai Inc. and METAvivor today announced the launch of Perseverance, a new initiative of the #ThisIsMBC campaign. Perseverance showcases imagery of a diverse group of 12 participants capturing the...
-
Dec 7, 2020Key data results:
Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2020 American Epilepsy Society (AES) Annual Meeting virtual conference....
-
Dec 1, 2020EMBARGOED UNTIL: 9:00 AM EST on December 4
Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 74th American Epilepsy Society (AES) Annual Meeting to be held from December...
Nov 20, 2020Results support 24 mg as the starting dose for LENVIMA in patients with radioactive iodine-refractory differentiated thyroid cancerEisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, at two starting doses:...
-
Nov 19, 2020Key findings reinforce safety and efficacy and dosing strategies of LENVIMA
Eisai announced today the presentation of three abstracts including investigational data in thyroid cancer and osteosarcoma at the European Society for Medical Oncology (ESMO) Asia Virtual...